Larry Luxner, senior correspondent for Rare Disease Advisor, interviews Damon Race, CEO of GeneVentiv Therapeutics. The North Carolina-based startup hopes to develop a universal gene therapy that will benefit patients with hemophilia A or B with or without inhibitors.
Listen to the podcast here: https://www.rarediseaseadvisor.com/news/hem-news-briefs/interview-damon-race-president-ceo-geneventiv-therapeutics/